Endpoint
The specific outcome a trial is designed to measure, fixed in advance: for example how long patients live, or how long before their cancer grows. A trial 'meets its endpoint' when the new treatment beats the comparison on that measure.
The primary endpoint determines the trial's size and its verdict; secondary endpoints (response rate, quality of life, safety, overall survival if not primary) add context but are not what the trial was powered to prove. Overall survival is the gold standard because it is unambiguous and matters most, but it takes years and is muddied when control patients later receive the new drug; progression-free survival, response rate and pathologic complete response are faster surrogates that may or may not translate into living longer. Choosing endpoints, and whether regulators should accept surrogates, is one of the most contested areas in oncology.
Pages like this
not linked directly; found by shared links- TermMedian survival
Shares Confidence interval, Reading a hazard ratio, Hazard ratio (HR), Overall survival (OS).
- TermPlacebo
Shares Blinded trial, Randomised trial, Clinical trial.
- TermBlinded independent central review (BICR)
Shares Blinded trial, Objective response rate (ORR), Progression-free survival (PFS).
- IdeaAn independent programme that validates surrogate endpoints, setting by setting
Shares Pathologic complete response (pCR), Objective response rate (ORR), Overall survival (OS), Progression-free survival (PFS).
- PersonMichael LeBlanc
Shares Hazard ratio (HR), Overall survival (OS), Progression-free survival (PFS).
- TermTime to progression (TTP) and time to next treatment (TTNT)
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Overall survival (OS), Progression-free survival (PFS).
- Key paperPrasad: most surrogate endpoints in cancer trials correlate poorly with survival
Shares Hazard ratio (HR), Objective response rate (ORR), Overall survival (OS), Progression-free survival (PFS).
- TermLandmark and milestone survival (5-year survival, median follow-up)
Shares Hazard ratio (HR), Overall survival (OS), Progression-free survival (PFS).